Rare loss of heterozygosity of the MTS1 and MTS2 tumor suppressor genes in differentiated human thyroid cancer

Hormone and Metabolic Research

Volumn 30, Issue 9, 1998, Pages 549-554

  Schulte, K M ^a,b   Staudt, S ^a   Niederacher, D ^a   Finken Eigen, M ^b   Kohrer K ^b   Goretzki, P E ^a   Roher H D ^a  

^a Dept of General and Trauma Surgery ^*  (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cancer; D9S171; IFNA; LOH; MTS1; MTS2; p15; p16; Thyroid

Indexed keywords

DNA;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER STAGING; CONTROLLED STUDY; GRAVES DISEASE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NODULAR GOITER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID ADENOMA; THYROID CANCER; THYROID DISEASE; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDITIS; TUMOR SUPPRESSOR GENE;

EID: 0031783822     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978930     Document Type: Article

References (39)

1. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990; 4: 1474-9
2. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab 1990; 71: 223-9
3. Goretzki PE, Lyons J, Stacy-Phipps S, Rosenau W, Demeure M, Clark OH, McCormick F, Roeher HD, Bourne HR. Mutational activation of RAS and CSP oncogenes in differentiated thyroid cancer and their biological implications. World J Surg 1992; 16: 576-82
4. Suarez HG, du Villard JA, Caillou B, Schlumberger M, Parmentier C, Monier R. gsp mutations in human thyroid tumours. Oncogene 1991; 6: 677-9
5. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 1995; 11: 2459-67
6. Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M, Fusco A. RET/ PTC oncogene activation is an early event in thryroid carcinogenesis. Oncogene 1995; 11: 1207-10
7. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992; 89: 1517-22
8. Bounacer A, Wicker R, Caillou B, Cailleux A, Sarasin A, Schlumberger M, Suarez H. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997; 15: 1263-73
9. Wright PA, Lemoine NR, Goretzki PE, Wyllie FS, Bond J, Hughes C, Roeher HD, Williams ED, Wynford-Thomas D. Mutation of the p53 gene in a differentiated human thryroid carcinoma cell line, but not in primary thyroid tumours. Oncogene 1991; 6: 1693-7
10. Nabori T, Miura K, Wu DJ, Lois A, Takabashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6
11. Kamb A. Cell cycle regulators and cancer. Trends Gen 1995; 11: 137-40
12. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440
13. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis TMJ, Skolnick MJ, Fujimura FK, Kamb A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 1995; 10: 1061-7
14. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993; 73: 499-511
15. Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A. Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene 1995; 11: 987-991
16. Wyllie FS, Dawson T, Bond JA, Goretzki P, Game S, Prime S, Wynford-Thomas D. Correlated abnormalities of transforming growth factor-beta 1 response and p53 expression in thyroid epithelial cell transformation. Mol Cell Endocrinol 1991; 76: 13-21
17. Grubeck-Loebenstein B, Buchan G, Sadeghi R, Kissonerghis M, Londei M, Turner M, Pirich K, Roka R, Niederle B, Kassal H, et al. Transforming growth factor beta regulates thyroid growth. Role in the pathogenesis of nontoxic goiter. J Clin Invest 1989; 83: 764-70
18. Hoelting T, Zielke A, Siperstein AE, Clark OH, Duh QY. Transforming growth factor-beta 1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines. J Clin Endocrinol Metab 1994; 79: 806-13
19. Calabro V, Strazzullo M, La Mantia G, Fidele M, Paulin C, Fusco A, Lania L Status and expression of the p16INK4 gene in human thyroid tumors and thryoid-tumor cell lines. Int J Cancer 1996; 67: 29-34
20. Liu ET, He M, Rajgopal U. Differential polymerase chain reaction in the analysis of gene dosage. Sem Cancer Biol 1993; 4: 47-58
21. Lubin MB, Elashoff JD, Wang SJ, Rotter Jl, Tarada H. Precise gene dosage determination by polymerase chain reaction: theory, methodology, and statistical approach. Mol Cell Probes 1991; 5: 307-17
22. An H-X, Niederacher D, Beckmann MV, Göhring U-J, Picard F, Scharl A, Picard F, Van Roeyen C, Schnürch H-G, Bender H-G. ERBB2 gene amplification detected by fluorescent differential polymerase chain reactionin paraffin-embedded breast carcinoma tissues. Int J Cancer 1995; 64: 291-7
23. Kishimoto Y, Sugio K, Hung J, Virmani A, McIntire D, Minna J, Gazdar A. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst 1995; 87: 1224-9
24. Cheng J, Jhanwar S, Yong Lu Y, Testa J. Homozygous deletions within 9p21-22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 1993; 53: 4761-3
25. Niederacher D, Beckmann MW, Scharl AFP, Schürch H-G, Bender HG. Biochemische und molekulargenetische Analyse von Onkogenen der c-erb Familie in Mammakarzinomen. Akt Onkol 1994; 79: 73-8
26. Schulte KM, Niederacher D, An H-X, Staudt S, Simon D, Beckmann MW, Goretzki PE. INT-2 gene amplification in differentiated human thyroid cancer. Exp Clin Endocrinol Diab 1996; 104: 101-4
27. Taton M, Lamy F, Roger PP, Dumont JE. General inhibition by transforming growth factor beta 1 of thyrotropin and cAMP responses in human thyroid cells in primary culture. Mol Cell Endocrinol 1993; 95: 13-21
28. Blaydes JP, Schlumberger M, Wynford-Thomas D, Wyllie FS. Interaction between p53 and TGF beta 1 in control of epithelial cell proliferation. Oncogene 1995; 10: 307-17
29. Blaydes P, Wynford-Thomas D. Loss of responsiveness to transforming growth factor β (TGFβ) is tightly linked to tumorigenicity in a model of thyroid tumour progression. Int J Cancer 1996; 65: 525-30
30. Serra R, Moses H. Tumor suppressor genes in the TGF-β signaling pathway. Nature Med 1996; 2: 390-1
31. Jones CJ, Shaw JJ, Wyllie FS, Gaillard N, Schlumberger M, Wynford-Thomas D. High frequency deletion of the tumour suppressor gene P16INK4a (MTS1) in human thyroid cancer cell lines. Mol Cell Endocrinol 1996; 116: 115-9
32. Zahn L, Kwiatkowski DJ. A 37-marker PCR-based genetic linkage map of human chromosome 9: observations on mutations and positive interference. Genomics 1995; 28: 140-6
33. Weaver-Feldhaus J, Gruis NA, Nezhausen S, Le Paslier D, Stockert E, Skolnick MH, Kamb A. Localization of a putative tumor suppressor gene by using homozygous deletion in melanomas. Proc Natl Acad Sci 1994; 91: 7563-7
34. Schultz D, Vanderveer L, Buetow K, Boente K, Ozols R, Hamilton T, Goodwin A. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 1995; 55: 2150-7
35. Goretzki PE, Gorelov V, Dotzenrath C, Witte J, Roeher HD. A frequent mutation/polymorphism in tumor suppressor gene INK4B (MTS-2) in papillary and medullary thyroid cancer. Surgery 1996; 120: 1081-8
36. Zhang SY, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsumaga S, Nabori T, Carson DA, Ridge JA, Goodrow TL. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994; 54: 5050-3
37. Spruck CH, Gonzales-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA. p16 in uncultured tumors. Nature 1994; 370: 183-4
38. Zhou X, Tarmin L, Hai-Yan, Jiang JY, Suzuki H, Rhyu MG, Abraham JM. The MTS1 gene is frequently mutated in primary esophageal tumors. Oncogene 1994; 9: 3737-41
39. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennet WP, Forrester K, Gerwin B, Serrano M, Beach DJ, Harris CC. Mutations and altered expression of p16ink4 in human cancer. Proc Natl Acad Sci 1994; 91: 11045-9